1 week Ago By ABMN Staff
Barclays PLC cut its stake in shares of Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO – Free Report ) by 42.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
The fund owned 121,753 shares of the biopharmaceutical company’s stock after selling 90,864 shares during the quarter. Barclays PLC’s holdings in Agios Pharmaceuticals were worth $4,000,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds have also recently added to or reduced their stakes in the company.
Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals in the fourth quarter worth $33,000. Wingate Wealth Advisors Inc. purchased a new stake in Agios Pharmaceuticals in the fourth quarter worth about $53,000.
Sterling Capital Management LLC boosted its position in shares of Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares in the last quarter.
KBC Group NV grew its position in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 611 shares during the period.
Finally, AlphaQuest LLC increased its stake in shares of Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 2,338 shares in the last quarter.
Insider Buying and Selling In related news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.
90, for a total transaction of $194,172.30. Following the transaction, the director now directly owns 149,220 shares of the company’s stock, valued at $3,864,798.
This trade represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link .
4.93% of the stock is currently owned by corporate insiders. Agios Pharmaceuticals Trading Up 0.
6 % Agios Pharmaceuticals ( NASDAQ:AGIO – Get Free Report ) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.
69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.
92% and a negative return on equity of 2.51%. On average, research analysts predict that Agios Pharmaceuticals, Inc.
will post -6.85 earnings per share for the current fiscal year. Wall Street Analyst Weigh In Several research firms have recently issued reports on AGIO.
HC Wainwright started coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 price target for the company.
StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock.
According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $56.57. Read Our Latest Stock Report on AGIO About Agios Pharmaceuticals ( Free Report ) Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. See Also Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc.
( NASDAQ:AGIO – Free Report ). Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
